Allogeneic hematopoietic stem cell transplantation after CD19-directed CAR T-cell therapy in children and adults with B-cell acute lymphoblastic leukemia: a GoCART coalition study on behalf of the PDWP, ALWP, and CTIWP of the EBMT
Year: 2026
Type: article
Study design: Observational Study
Abstract: Hematopoietic stem cell transplantation (HSCT) can rescue B-cell acute lymphoblastic leukemia (B-ALL) recurring after CD19-directed chimeric antigen receptor T cells (CAR19 T cells). However, in patients at high risk of relapse, the indication for and timing of consolidative HSCT are controversial. We retrieved data on 112 patients who received an HSCT at a median of 6.1 months after CAR19 T-cell infusion. Indication for subsequent HSCT were: (I) Rescue in 72 (64%) patients for disease recurrence; (II) Pre-emptive in 21 (19%) for loss of B-cell aplasia; (III) Consolidative in 19 patients (17%). The 2-year post-transplant Leukemia-Free Survival (LFS) was 54% and the 2-year cumulative incidence of relapse was 32%. Children had better LFS than adults (63% vs 38%). Older age was associated with inferior LFS (HR per 10-year increase 1.30; p= 0.01) and patients receiving a rescue HSCT had a significantly lower 2-year LFS (41%), compared to pre-emptive (74%) and consolidative HSCT (78%), respectively (p=0.002). Haploidentical donor was also associated with inferior LFS (HR: 2.21 95%CI: 1.15-4.25, p=0.02). This "real-world" study corroborates the need to identify patients at higher risk of relapse and optimization of strategies to improve outcome in patients with R/R B-ALL receiving CD19-directed CAR T cells.
Source: Haematologica
Authors: Giorgio Ottaviano, Anna Alonso-Saladrigues, Valentin Ortiz-Maldonado, Jacques-Emmanuel Galimard, Shatha Farhan, Sowjana Vuyyala, Eva Michel, Fizza Imran, Nuria Martinez-Cibrián, Samppa Ryhänen, Andishe Attarbaschi, Stephan Mielke, Jürgen Kuball, Antonio Perez Martinez, Yves Beguin, Arnon Nagler, Anne-Charlotte Teyssier, Soeren Lykke Petersen, Pere Barba, Júlia Marsal, Julio Delgado, Krzysztof Kalwak, Fabio Ciceri, Annalisa Ruggeri, Sebastian Giebel, Susana Rives, Adriana Balduzzi
Institutions: Azienda Ospedaliera San Gerardo, Hospital Sant Joan de Déu Barcelona, Institut de Recerca Sant Joan de Déu, Hospital Clínic de Barcelona, European Society for Blood and Marrow Transplantation, Henry Ford Health, Henry Ford Hospital, Mayo Clinic, University of Helsinki, St Anna Children's Hospital, St. Anna Children's Cancer Research Institute, Medical University of Vienna, Karolinska Institutet, University Medical Center Utrecht, Hospital Universitario La Paz, University of Liège, Centre Hospitalier Universitaire de Liège, Sheba Medical Center, Centre Hospitalier Universitaire de Montpellier, Copenhagen University Hospital, Rigshospitalet, Vall d'Hebron Hospital Universitari, University of Wrocław, Wroclaw Medical University, IRCCS Ospedale San Raffaele, The Maria Sklodowska-Curie National Research Institute of Oncology, University of Milano-Bicocca
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: allogeneic hematopoietic stem cell transplantation, CD19 CAR T-cell therapy, B-cell acute lymphoblastic leukemia, relapsed/refractory B-ALL, consolidation therapy, preemptive transplantation, leukemia-free survival, relapse risk, haploidentical donor, age as prognostic factor, pediatric and adult patients
Open Access status: gold
Estimated APC paid: $2,157
Funder: Ministero della Salute
OpenAlex ID: W7236798412
